Astellas Pharma Receives FDA Approval for Hyponatremia Drug VAPRISOL.Tokyo, Japan, Jan 4, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Astellas Pharma announced on January 4 that its US subsidiary Astellas Pharma US has received approval for VAPRISOL, Astellas' proprietary agent for treating hyponatremia Hyponatremia Definition The normal concentration of sodium in the blood plasma is 136-145 mM. Hyponatremia occurs when sodium falls below 130 mM. Plasma sodium levels of 125 mM or less are dangerous and can result in seizures and coma. , from the US Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ). VAPRISOL is the world's first agent approved for treating hyponatremia. With this approval, the agent is now applicable for treating euvolemic hyponatreamia. In addition, Astellas Pharma US has received an approval letter from the FDA for the agent as a treatment for hypervolemic hyponatremia. Discovered and developed by Astellas Pharma, VAPRISOL is an arginine arginine (är`jənĭn), organic compound, one of the 20 amino acids commonly found in animal proteins. Only the l-stereoisomer participates in the biosynthesis of proteins. vasopression antagonist for improving serum sodium levels. Going forward, Astellas aims to obtain approval for the indication of hypervolemic hyponatremia at the earliest date possible. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion